Rothschild & Co Redburn Begins Coverage on Bruker (NASDAQ:BRKR)

Equities research analysts at Rothschild & Co Redburn began coverage on shares of Bruker (NASDAQ:BRKR) in a research note issued to investors on Thursday, MarketBeat.com reports. The brokerage set a “buy” rating and a $60.00 price target on the medical research company’s stock. Rothschild & Co Redburn’s price objective suggests a potential upside of 26.93% from the company’s previous close.

Several other brokerages also recently issued reports on BRKR. TD Cowen lifted their price target on shares of Bruker from $40.00 to $42.00 and gave the company a “hold” rating in a report on Tuesday, November 4th. Jefferies Financial Group set a $60.00 target price on shares of Bruker and gave the company a “buy” rating in a research note on Monday, August 4th. Wells Fargo & Company reduced their target price on Bruker from $50.00 to $48.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Citigroup dropped their price target on Bruker from $40.00 to $38.00 and set a “neutral” rating for the company in a report on Monday, August 4th. Finally, Barclays lifted their price objective on Bruker from $40.00 to $45.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $50.25.

Bruker Stock Performance

BRKR opened at $47.27 on Thursday. The stock’s 50 day simple moving average is $37.31 and its 200-day simple moving average is $37.32. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31. The stock has a market cap of $7.18 billion, a PE ratio of 90.91, a P/E/G ratio of 5.31 and a beta of 1.26. Bruker has a 1 year low of $28.53 and a 1 year high of $64.64.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share for the quarter, topping analysts’ consensus estimates of $0.33 by $0.12. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The firm had revenue of $860.50 million for the quarter, compared to the consensus estimate of $847.40 million. During the same quarter in the previous year, the company earned $0.60 earnings per share. The business’s revenue was down .5% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. Sell-side analysts forecast that Bruker will post 2.69 EPS for the current year.

Insiders Place Their Bets

In other news, Director Cynthia M. Friend sold 3,535 shares of Bruker stock in a transaction on Friday, September 12th. The stock was sold at an average price of $32.25, for a total value of $114,003.75. Following the completion of the sale, the director directly owned 18,016 shares of the company’s stock, valued at approximately $581,016. This trade represents a 16.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John A. Ornell sold 6,233 shares of the business’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $39.00, for a total value of $243,087.00. Following the sale, the director owned 35,212 shares of the company’s stock, valued at approximately $1,373,268. The trade was a 15.04% decrease in their position. The SEC filing for this sale provides additional information. 27.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of BRKR. Amundi lifted its holdings in Bruker by 373.3% during the first quarter. Amundi now owns 42,503 shares of the medical research company’s stock worth $1,774,000 after acquiring an additional 33,522 shares in the last quarter. Vaughan Nelson Investment Management L.P. increased its holdings in shares of Bruker by 71.2% in the second quarter. Vaughan Nelson Investment Management L.P. now owns 1,293,645 shares of the medical research company’s stock worth $53,298,000 after acquiring an additional 537,845 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in shares of Bruker by 35.6% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 40,450 shares of the medical research company’s stock worth $1,717,000 after purchasing an additional 10,624 shares during the period. Public Employees Retirement System of Ohio lifted its holdings in shares of Bruker by 60.8% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 55,672 shares of the medical research company’s stock valued at $2,294,000 after purchasing an additional 21,043 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D grew its position in shares of Bruker by 39.0% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 51,828 shares of the medical research company’s stock valued at $2,135,000 after purchasing an additional 14,547 shares during the period. Institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.